Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model

Fang, Xiankang; Du, Zhiqiang; Duan, Chunling; Zhan, Shanshan; Zhu, Mengyu; Shi, Jinqiao; Meng, Juan; Zhang, Xianhua; Yang, Maiyun; Zuo, Yajun

doi:10.1016/j.lfs.2020.118966

Cited by 13 publications

(8 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GO-enriched lipolytic and metabolic pathway effector genes were largely overlapped, and we analyzed expression levels of several key node genes using qPCR. These genes include fatty acid beta-oxidation pathway-related acox1 , acadl , and acaa1 , alpha-oxidation of 3-methyl branched fatty acids pathway-related phyh , and gluconeogenesis regulates associated pck1 , and lpin1 , which encodes enzyme that catalyzes the penultimate step in triglyceride synthesis including the dephosphorylation of phosphatidic acid to yield diacylglycerol (( Fang et al., 2021 ; He et al., 2020 ; Schofield and McDonough 2007 ; Wang et al., 2021 ; Xu et al., 2020 ). Results showed that all these genes were significantly upregulated in VAT of scd5 −/− , and restored by ω3-PUFA ( Figures 6 E–6F).…”

Section: Resultsmentioning

confidence: 99%

Identification of Scd5 as a functional regulator of visceral fat deposition and distribution

Zhang¹,

Sun²,

Zhang³

et al. 2022

iScience

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Identification of Scd5 as a functional regulator of visceral fat deposition and distribution

Zhang¹,

Sun²,

Zhang³

et al. 2022

iScience

View full text Add to dashboard Cite

“…The study found that the average weight decreased by 10.05 kg after 3 months of treatment ( 40 ). In animal studies, Fang ( 42 ) et al. studied the pharmacological and pharmacokinetic efficacy of BN in C57BL/6 and ob/ob mice.…”

Section: Experimental Evidence Of Glp-1r Agonistsmentioning

confidence: 99%

“…There were significant changes in fatty acid β-oxidation (Ppara, Acadl, Acox1), mitochondrial function (Mfn1, Mfn2), antioxidation (Sod2), SIRT1. This suggests that BN may be an effective treatment for obesity and NASH ( 42 ). A clinical study involving 78 non-diabetic overweight/obese patients found that BN may be a more effective treatment option for overweight/obese Chinese than metformin ( 43 ).…”

Section: Experimental Evidence Of Glp-1r Agonistsmentioning

confidence: 99%

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Wang

Wang²,

Yang³

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists.

show abstract

“…A 72-week, double-blind phase 2 trial showed that once-daily administration of semaglutide had a significant therapeutic effect on NASH ( 193 ). Long term use of beinaglutide, a recombinant human GLP-1(7-36) acid, was demonstrated to reduce the body weight and improve steatosis ( 194 ). Several studies found that GLP-1RAs might have direct effects on adipogenesis, lipotoxicity, fatty acid oxidation, cytokines related to hepatitis and fibrosis, and intestinal microbiota ( 193 , 195 ).…”

Section: Effects On Non-alcoholic Fatty Liver Diseasementioning

confidence: 99%

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

et al. 2021

View full text Add to dashboard Cite

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and minimal side effects. Studies have found that GLP-1R is widely distributed on pancreatic and other tissues and has multiple biological effects, such as reducing neuroinflammation, promoting nerve growth, improving heart function, suppressing appetite, delaying gastric emptying, regulating blood lipid metabolism and reducing fat deposition. Moreover, GLP-1RAs have neuroprotective, anti-infectious, cardiovascular protective, and metabolic regulatory effects, exhibiting good application prospects. Growing attention has been paid to the relationship between GLP-1RAs and tumorigenesis, development and prognosis in patient with T2DM. Here, we reviewed the therapeutic effects and possible mechanisms of action of GLP-1RAs in the nervous, cardiovascular, and endocrine systems and their correlation with metabolism, tumours and other diseases.

show abstract

Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model

Cited by 13 publications

References 55 publications

Identification of Scd5 as a functional regulator of visceral fat deposition and distribution

Identification of Scd5 as a functional regulator of visceral fat deposition and distribution

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Contact Info

Product

Resources

About